胰岛素和糖尿病药物会把葡萄糖从血液和细胞中拉出来，造成一种体内的“饥荒”。
原始表述
الأنسولين وأدوية السكر تسحب السكر من الدم والخلايا، فتسبب «مجاعة» داخل الجسم
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
胰岛素和糖尿病药物会把葡萄糖从血液和细胞中拉出来，造成一种体内的“饥荒”。
出处
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/oral-diabetes-drugs/
- 归属的不确定性
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): similar_idea_only. The image of an 'internal famine' (مجاعة) was found in his transcripts only in other contexts (fasting, war), not in relation to insulin or diabetes drugs. A passage stating that anyone who lowers blood sugar or takes insulin, Galvus, Forxiga or Mounjaro will be harmed (5Pr4BCDlQeI) expresses a related idea.
- 所声称的机制
Glucose-lowering drugs deprive cells of fuel.
- 所声称的健康影响
Cell starvation
- 涉及人群
People taking glucose-lowering drugs
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live!فلسفة الصيام مع السحور المحترم (打开来源)
- 发布日期
- 2026年2月23日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
اللي هيوطي السكر هيتفشخ اللي هياخد انسولين هيتفشخ اللي هياخد دوا جالفس هيتفشخ اللي هياخد فورسيجا هيتفشخ اللي هياخد مونجارو هيتفشخ
Whoever lowers the sugar will be wrecked; whoever takes insulin will be wrecked; whoever takes the drug Galvus will be wrecked; whoever takes Forxiga will be wrecked; whoever takes Mounjaro will be wrecked (vulgar colloquial verb).
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (打开来源)
- 发布日期
- 2026年3月26日
- 时间戳
- 1:16:57 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Similar idea only; the 'famine' image is not in this passage.
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Diabetes drugs starve the body by removing glucose from blood and cells.
2. 哪些内容可证实是正确的？
Insulin and sulfonylureas can cause hypoglycaemia, which deprives the brain of glucose; this is the main harm of over-treatment (A-INS-14, A-INS-15, A-INS-16). Trials of intensive glucose lowering roughly doubled to tripled severe hypoglycaemia (HR 2.48, 1.91-3.21) without reducing mortality (I-ODD-108), and in ACCORD targeting near-normal HbA1c in high-risk type 2 diabetes increased mortality (257 vs 203 deaths; HR 1.22, 1.01-1.46) (A-INS-01). This is why guidelines individualise targets (I-INS-10). SGLT2 inhibitors can cause a starvation-like ketotic state in some situations (I-ODD-10).
3. 哪些内容是错误或夸大的？
In hyperglycaemia the problem is not lack of glucose in the blood but too much; insulin moves glucose into muscle and fat cells where it is used or stored, so cells are not starved. Insulin deficiency, not insulin, produces an internal 'famine' with breakdown of fat and muscle (I-INS-08).
4. 哪些内容仍不明确？
No study has tested an 'internal famine' concept because it is not a defined physiological state. The archive's wording ('internal famine') was found in Elawady's transcripts only in other contexts (fasting, war), so it is uncertain whether he used this image for insulin.
5. 哪些研究支持该说法？
None for an 'internal famine'. Mixed: A-INS-14, A-INS-15 (hypoglycaemia kernel only; hypoglycaemia uncommon and mostly a marker of vulnerability), I-ODD-10.
6. 哪些研究与该说法相矛盾？
I-INS-08 (insulin deficiency causes the catabolic state), I-INS-03 and I-INS-104 (intensive insulin therapy in type 1 diabetes lowered mortality over 27 years: HR 0.67, 0.46-0.99), I-INS-134 (NICE NG17), I-ODD-16 (ADA 2026: insulin essential in type 1 diabetes).
7. 对德国和欧洲而言情况如何？
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
低血糖是一种真实存在的风险，需要调整剂量并进行患者教育；但它并不是糖尿病治疗的普遍特性。
评估详情
- 证据确定性的依据
Glucose-lowering drugs act by increasing glucose uptake into tissues (insulin), reducing hepatic glucose output (metformin), or excreting excess glucose (SGLT2). Only overdose/hypoglycaemia deprives the brain of glucose. The 'famine' concept has no empirical support apart from that kernel.
- 来源质量
Archive paraphrase plus own words.
- 地区可推广性
Universal.
- 个体例外情况
Older or frail people and those on insulin/sulfonylureas are at higher hypoglycaemia risk.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: Do insulin and other glucose-lowering drugs deprive cells of glucose ('internal famine'), and what is the actual effect of glucose-lowering treatment on cellular fuel supply, hypoglycaemia and mortality?
研究问题详解 (PICO)
- 人群
- People with type 1 or type 2 diabetes
- 干预或暴露
- Insulin and other glucose-lowering drugs (standard or intensive use)
- 对照
- No/less intensive treatment
- 地域范围
- universal biology
- 结局指标
- Severe hypoglycaemia
- All-cause mortality
- DKA / catabolic state from insulin deficiency
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743 随机对照试验已核查全文ACCORD: targeting near-normal HbA1c with intensive therapy increased mortality and severe hypoglycaemia in high-risk type 2 diabetes.
- 实际结果
- Deaths 257 vs 203; HR 1.22 (1.01-1.46); trial stopped early.
- 方法学质量
- high (large RCT)
- 相关性
- indirect - shows harm of over-intensive lowering, not cellular starvation
- 局限
- Mechanism of excess deaths unclear; older drug strategies.
Very tight sugar control: fewer heart attacks, more severe low sugars
Control Group (Turnbull FM et al.). Diabetologia 2009 · PMID 19655124 · DOI 10.1007/s00125-009-1470-0 Meta分析已核查摘要新增Meta-analysis of intensive-control trials: severe hypoglycaemia about 2.5-fold higher; mortality unchanged.
- 实际结果
- Major hypoglycaemia HR 2.48 (1.91-3.21); death HR 1.04 (0.90-1.20); MI HR 0.85.
- 方法学质量
- high
- 相关性
- indirect
- 局限
- Group-level data.
哪些证据不支持该说法？
Long-term survival after intensive insulin treatment in type 1 diabetes
Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107 随机对照试验已核查摘要新增DCCT/EDIC: intensive insulin therapy in type 1 diabetes lowered mortality over 27 years.
- 实际结果
- HR 0.67 (0.46-0.99); -109 deaths per 100,000 patient-years.
- 方法学质量
- high (randomised origin, long follow-up)
- 相关性
- direct for insulin
- 局限
- Borderline precision.
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1 叙述性综述全文，含结构化偏倚风险评估DKA review: insulin deficiency, not insulin, produces the catabolic, starvation-like state with fat breakdown and ketoacidosis.
- 实际结果
- Narrative review (Nat Rev Dis Primers).
- 方法学质量
- moderate (expert review of established physiology)
- 相关性
- direct for mechanism
- 局限
- Narrative.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Insulin moves glucose from the blood into muscle and fat cells; it does not pull glucose out of cells. The starvation-like state ('famine') in diabetes is caused by insulin deficiency, which leads to DKA. The true kernel is that excessive glucose lowering, mainly with insulin or sulfonylureas, can cause hypoglycaemia and, in ACCORD, aggressive near-normal targets increased mortality; this is why targets are individualised.
为什么有些研究权重更大
Physiology and RCTs (DCCT/EDIC, ACCORD, meta-analysis) outweigh the image of 'famine', which has no empirical basis beyond hypoglycaemia.
因果关系是否已确立？ 是，已确立 Causality is established for hypoglycaemia from overdosing and for harm from over-intensive targets in high-risk patients; a general cellular famine from glucose-lowering drugs is incompatible with established physiology.
仍存在的不确定性
Mechanisms of excess mortality in ACCORD.
合理的结论
The claim is mostly false; only over-treatment causing hypoglycaemia is a real, managed risk. Stopping insulin is dangerous.
为什么研究结果看起来互相矛盾？
ACCORD (harm) and DCCT/EDIC or UKPDS follow-up (benefit) answer different questions: ACCORD tested very aggressive targets in older high-risk type 2 patients with older drugs; DCCT/UKPDS tested moderate intensification earlier in disease. Both support individualised targets, neither supports avoiding glucose-lowering treatment.
这是否取决于国家？
- 一般生物学效应
- Drug pharmacology and physiology are universal.
- 饮食习惯
- Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable (same active substances; generics widely used in Egypt).
- 法律规则
- Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
- 实际监测数据
- No Egypt-specific pharmacovigilance data were found for this outcome.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Approximate absolute mortality increase – 5.01% vs 3.96% assuming equal arm sizes (arm sizes not in abstract): +1.05 percentage points, NNH about 95 over 3.5 years. 已重新计算
- CI symmetry – All HRs symmetric on log scale. 已重新计算
- Absolute benefit – 1 death prevented per about 917 patient-years; about 2.9 fewer deaths per 100 over 27 years. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Cellular fuel deprivation ('famine') from glucose-lowering drugs vs physiological effect and mortality
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness: no study tests 'famine' as such; judged on physiology and outcome trials
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · 原始文献
Insulin treatment is essential for type 1 diabetes; insulinopenia contributes to ketoacidosis and life-threatening catabolism (rec. 9.1). - ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
ACCORD stopped early for higher mortality with intensive glucose lowering; select individual goals that avoid hypoglycaemia; people on intensive insulin should not stop basal insulin even if not eating. - NICE: Type 1 diabetes in adults: diagnosis and management (NG17), last updated 17 August 2022 (2022) · 原始文献
Insulin regimens for all adults with type 1 diabetes; sick-day rules to adjust insulin during illness; ketone monitoring to prevent DKA.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | ("intensive glycaemic control"[tiab] OR "intensive glycemic control"[tiab] OR "intensive glucose"[tiab]) AND (mortality[tiab] OR hypoglycaemia[tiab] OR hypoglycemia[tiab]) AND ("Cochrane Database Syst Rev"[ta] OR meta-analysis[pt]) | 支持性证据 | 50 | |
| Europe PMC | 2026年10月26日 | ("intensive treatment" OR "intensive therapy") AND "type 1 diabetes" AND mortality AND (DCCT OR EDIC) | 反对性证据 | 803 | |
| PubMed | 2026年10月26日 | "intensive diabetes therapy"[tiab] AND mortality[ti] AND "type 1 diabetes"[tiab] AND (DCCT[tiab] OR EDIC[tiab]) | 反对性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (insulin OR sulfonylurea) AND ("severe hypoglycemia" OR "severe hypoglycaemia") AND (dementia OR "cognitive" OR mortality) AND ("meta-analysis" OR cohort) | 支持性证据 | 5468 | |
| PubMed | 2026年10月26日 | (insulin[ti] OR "glucose-lowering"[ti]) AND (hypoglycemia[ti] OR hypoglycaemia[ti]) AND (brain[tiab] OR neuroglycopenia[tiab] OR cognitive[tiab]) AND (cohort[tiab] OR meta-analysis[pt]) | 支持性证据 | 2 | |
| Europe PMC | 2026年10月26日 | (TITLE:insulin) AND ("glucose uptake") AND ("skeletal muscle") AND (clamp OR "insulin action") AND (human OR humans) | 反对性证据 | 3770 | |
| ADA Standards of Care 2026, Sections 6 and 9 (PubMed Central) | 2026年10月26日 | Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690178/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/; keyword review: ACCORD, hypoglycemia, insulin essential, basal insulin. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central. | 指南 | 1 | |
| NICE NG17 | 2026年10月26日 | Fetched https://www.nice.org.uk/guidance/ng17/chapter/Recommendations; Recommendations chapter: insulin regimens, sick-day rules, ketone monitoring | 指南 | 1 |
待解决的问题
None that would change the conclusion.
核查深度如何？
9 项相关研究：6 项核查了全文（其中 4 项进行了结构化偏倚风险评估），3 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (高)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本错误 (高)
New evidence (DCCT/EDIC mortality, intensive-control meta-analysis, NICE NG17) is consistent with the existing assessment. ACCORD is added explicitly as the strongest evidence for the hypoglycaemia/over-treatment kernel, which is why the verdict stays MOSTLY_FALSE rather than FALSE.
新来源: I-ODD-108 I-INS-104 I-INS-134
通俗解释
糖尿病药物不会让身体挨饿。例如，胰岛素帮助糖分进入需要它的肌肉细胞。真正的风险是剂量过高导致低血糖，医生会通过调整剂量来努力预防这种情况。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (4)
-
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1叙述性综述独立交叉核查全文，含结构化偏倚风险评估DKA is an emergency that can kill; it is treated with fluids, insulin and salts, and insulin must not be stopped in type 1 diabetes even when not eating.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Epidemiology, pathogenesis, diagnosis and management of DKA
- 研究是如何开展的？
Narrative expert review (Nature Reviews Disease Primers)
- 研究了多少人、动物或样本？
not applicable; Adults and children with diabetes
- 实际发现了什么？
DKA is diagnosed by high glucose, ketones and acid; it kills <1% when treated in rich countries but up to 26-41% where treatment is lacking; treatment is fluids, insulin and potassium, and insulin must never be stopped in type 1 diabetes even when not eating.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
DKA is an emergency.
- 该研究有哪些局限？
Narrative expert review without systematic methods; one author has research support from insulin makers.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
International.
- 从该研究中明确不能得出什么结论？
Quantitative estimates.
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401随机对照试验独立交叉核查已核查摘要★ 关键研究Intensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- 研究是如何开展的？
Multicentre RCT (DCCT)
- 研究了多少人、动物或样本？
1,441; Insulin-dependent (type 1) diabetes
- 实际发现了什么？
Large reductions in all microvascular complications.
- 观察到的效应有多大？
Retinopathy -76%
- 研究结果对日常生活意味着什么？
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- 该研究有哪些局限？
Open-label; Selected young population
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
North American; universally accepted.
- 从该研究中明确不能得出什么结论？
Effects in type 2 diabetes directly.
-
Long-term survival after intensive insulin treatment in type 1 diabetes
Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107随机对照试验独立交叉核查已核查摘要★ 关键研究People who received intensive insulin treatment for about 6.5 years had about one third lower death risk 27 years later.
Intensive insulin therapy reduced mortality over 27 years.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether intensive insulin therapy affects long-term survival.
- 研究是如何开展的？
Follow-up of a randomised trial.
- 研究了多少人、动物或样本？
1,441 young adults with T1D.
- 实际发现了什么？
43 vs 64 deaths; HR 0.67.
- 观察到的效应有多大？
-109 deaths per 100,000 patient-years.
- 研究结果对日常生活意味着什么？
Good insulin treatment helps people with type 1 diabetes live longer.
- 该研究有哪些局限？
Few deaths; later years observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'insulin does not treat diabetes'.
- 研究结果是否适用于德国和欧洲？
Applicable to Europe.
- 从该研究中明确不能得出什么结论？
Cannot separate effects of later care.
-
NICE guideline NG17: Type 1 diabetes in adults: diagnosis and management
National Institute for Health and Care Excellence (NICE). NICE guideline 2015指南 / 立场声明独立交叉核查已核查全文★ 关键研究UK guideline: insulin is standard for all adults with T1D; DKA treated with IV saline and IV insulin.
Insulin is standard essential therapy; sick-day rules adjust rather than stop insulin.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
National guidance.
- 研究是如何开展的？
Evidence-based guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Rec 1.7.1: offer multiple daily injection basal-bolus insulin regimens as the regimen of choice for all adults with T1D. Rec 1.10.1: consider ketone monitoring as part of sick-day rules. Recs 1.10.5-1.10.7: use isotonic saline for fluid replacement in DKA and give intravenous insulin by infusion. Misdiagnosis of T1D as T2D 'could lead to the person not receiving insulin treatment and a subsequent risk of diabetic ketoacidosis'.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
UK guideline: insulin is standard for all adults with T1D; DKA treated with IV saline and IV insulin.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
Contradicts insulin-free management.
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Not applicable.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (5)
-
Ketoacidosis with normal blood sugar on SGLT2 drugs
Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843病例系列 / 病例报告独立交叉核查全文，含结构化偏倚风险评估Several patients developed ketoacidosis with near-normal sugar, so it was recognised late.
该研究是否支持这一具体说法？ 是 · 方法学质量: 极低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Describe euglycaemic DKA with SGLT2 inhibitors
- 研究是如何开展的？
Case series
- 研究了多少人、动物或样本？
9 individuals, 13 episodes; Patients with T1D or T2D on SGLT2 inhibitors
- 实际发现了什么？
13 episodes in 9 patients on canagliflozin (7 with off-label type 1 diabetes); glucose often near normal, delaying diagnosis; all recovered with IV fluids and insulin.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Check ketones when unwell on SGLT2 drugs.
- 该研究有哪些局限？
Incidental case collection, no denominator, mostly off-label type 1 use, all on canagliflozin.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
US.
- 从该研究中明确不能得出什么结论？
How often this happens; that every SGLT2 inhibitor (e.g. dapagliflozin) carries the same risk (inferred, not shown here).
-
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究People who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Link between severe hypoglycaemia and mortality in ACCORD
- 研究是如何开展的？
Retrospective epidemiological analysis within an RCT (ACCORD)
- 研究了多少人、动物或样本？
10,194; ACCORD participants with hypoglycaemia assessment
- 实际发现了什么？
Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.
- 观察到的效应有多大？
aHR 1.41 (1.03-1.93) intensive arm
- 研究结果对日常生活意味着什么？
Severe hypoglycaemia is a danger sign to avoid.
- 该研究有哪些局限？
Post-hoc observational analysis; Confounding by frailty
- 它对 Elawady 的具体说法说明了什么？
Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
That hypoglycaemia caused the ACCORD excess mortality.
-
Severe hypoglycaemia in ADVANCE
Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估Severe low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Severe hypoglycaemia and vascular events/death
- 研究是如何开展的？
Post-hoc cohort analysis of an RCT (ADVANCE)
- 研究了多少人、动物或样本？
11,140; ADVANCE participants with type 2 diabetes
- 实际发现了什么？
aHR 2.69 death.
- 观察到的效应有多大？
aHR 2.69 (1.97-3.67)
- 研究结果对日常生活意味着什么？
Avoid severe hypoglycaemia.
- 该研究有哪些局限？
Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
Causation.
-
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743随机对照试验被 Tayebat 档案网站引用已核查全文★ 关键研究Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
- 研究是如何开展的？
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
- 研究了多少人、动物或样本？
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
- 实际发现了什么？
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
- 观察到的效应有多大？
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
- 研究结果对日常生活意味着什么？
Very strict sugar targets are not good for everyone, especially older people with heart disease.
- 该研究有哪些局限？
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
- 它对 Elawady 的具体说法说明了什么？
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
-
Very tight sugar control: fewer heart attacks, more severe low sugars
Control Group (Turnbull FM et al.). Diabetologia 2009 · PMID 19655124 · DOI 10.1007/s00125-009-1470-0Meta分析独立交叉核查已核查摘要★ 关键研究MI -15%, major hypoglycaemia about 2.5 times more frequent; death unchanged.
Confirms the hypoglycaemia kernel; does not support a general cellular 'famine'.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pool trials of intensive vs standard glucose control.
- 研究是如何开展的？
Pre-planned meta-analysis.
- 研究了多少人、动物或样本？
27,049 people.
- 实际发现了什么？
Modest MACE reduction; more severe hypoglycaemia; no mortality change.
- 观察到的效应有多大？
MACE HR 0.91; hypoglycaemia HR 2.48.
- 研究结果对日常生活意味着什么？
Over-treating sugar has a real cost; targets should be individual.
- 该研究有哪些局限？
Older drug strategies.
- 它对 Elawady 的具体说法说明了什么？
Supports only the hypoglycaemia kernel.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That glucose-lowering drugs starve cells in general.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本错误 基本错误：胰岛素是把葡萄糖送进细胞，糖尿病中真正的“饥荒”来自缺乏胰岛素；其中正确的内核是，过度治疗可能导致危险的低血糖，而且在ACCORD试验中，非常激进的控制目标增加了死亡。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Diabetic ketoacidosis.. Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.. Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107
- NICE guideline NG17: Type 1 diabetes in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.. Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
- Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
- Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
- Intensive glucose control and macrovascular outcomes in type 2 diabetes.. Control Group (Turnbull FM et al.). Diabetologia 2009 · PMID 19655124 · DOI 10.1007/s00125-009-1470-0